Daniel Bradbury sold $273k of CSTL
director at CASTLE BIOSCIENCES INC. 7,867 shares at an average of $34.73, traded Nov 1, 2024, filed Nov 5, 2024.
Score components
- +15RoleDirector
- +13Trade size$273k at market
- +10Share of holdings soldSold 39% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.2%, 3m -9.6%, 6m -46.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001447362-24-000172, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 1, 2024 | SOpen-market sale Common Stockindirect: By LLC10b5-1 | -1,322 | $33.90 | $45k | 18,746 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stockindirect: By Daniel Bradbury Irrecovable Descendant's Trust10b5-1 | -375 | $33.90 | $13k | 5,325 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stockindirect: By Annette Bradbury Irrecovable Descendant's Trust10b5-1 | -375 | $33.90 | $13k | 5,325 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stockindirect: By LLC10b5-1 | -2,686 | $34.92 | $94k | 16,060 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stockindirect: By Daniel Bradbury Irrecovable Descendant's Trust10b5-1 | -763 | $34.92 | $27k | 4,562 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stockindirect: By Annette Bradbury Irrecovable Descendant's Trust10b5-1 | -763 | $34.92 | $27k | 4,562 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stockindirect: By LLC10b5-1 | -1,009 | $35.33 | $36k | 15,051 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stockindirect: By Daniel Bradbury Irrecovable Descendant's Trust10b5-1 | -287 | $35.33 | $10k | 4,275 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stockindirect: By Annette Bradbury Irrecovable Descendant's Trust10b5-1 | -287 | $35.33 | $10k | 4,275 | Nov 5, 2024 |
Related signals
Other insiders at CASTLE BIOSCIENCES INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | CASTLE BIOSCIENCES INC | Derek J Maetzold Pres. & Chief Exec. Officer | $516k 14,496 shares | -49% | |
| 16Weak | CASTLE BIOSCIENCES INC | Kristen M Oelschlager Chief Operating Officer | $149k 4,153 shares | -24% | |
| 28Weak | CASTLE BIOSCIENCES INC | Tobin W Juvenal Chief Commercial Officer | $232k 6,577 shares | -11% | |
| 33Weak | CASTLE BIOSCIENCES INC | Derek J Maetzold Pres. & Chief Exec. Officer | $512k 14,496 shares | -48% | |
| 27Weak | CASTLE BIOSCIENCES INC | Tobin W Juvenal Chief Commercial Officer | $223k 6,600 shares | -10% | |
| 32Weak | CASTLE BIOSCIENCES INC | Derek J Maetzold Pres. & Chief Exec. Officer | $465k 14,518 shares | -48% | |
| 16Weak | CASTLE BIOSCIENCES INC | Kristen M Oelschlager Chief Operating Officer | $139k 4,152 shares | -24% | |
| 17Weak | CASTLE BIOSCIENCES INC | Tobin W Juvenal Chief Commercial Officer | $57k 1,730 shares | -3% | |
| 45Moderate | CASTLE BIOSCIENCES INC | Derek J Maetzold Pres. & Chief Exec. Officer | $616k 18,560 shares | -55% | |
| 25Weak | CASTLE BIOSCIENCES INC | Kristen M Oelschlager Chief Operating Officer | $178k 8,587 shares | -22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.